Search Results - Carcereny Costa, E.

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    141P Unveiling the likely pharmacological mechanisms of brigatinib on brain metastasis in ALK+ patients with non-small cell lung cancer: A systems biology and artificial intelligence-based approach

    141P Unveiling the likely pharmacological mechanisms of brigatinib on brain metastasis in ALK+ patients with non-small cell lung cancer: A systems biology and artificial intelligen... by Costa, E. Carcereny, Artigas, L., Martinez-Cardús, A., López, A., Camprodon, M. Coma

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

    Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial by Michels, S., Massutí, B., Vasyliv, I., Stratmann, J., Frank, J., Adams, A., Felip, E., Grohé, C., Rodriguez-Abreu, D., Bischoff, H., Carcereny i Costa, E., Corral, J., Pereira, E., Fassunke, J., Fischer, R.N., Insa, A., Koleczko, S., Nogova, L., Reck, M., Reutter, T., Riedel, R., Schaufler, D., Scheffler, M., Weisthoff, M., Provencio, M., Merkelbach-Bruse, S., Hellmich, M., Sebastian, M., Büttner, R., Persigehl, T., Rosell, R., Wolf, J.

    Published in ESMO open
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  3. 3
    OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC

    OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC by Krebs, M.G., Helland, Å., Carcereny Costa, E., Arriola Aperribay, E., Dómine Gómez, M., Trigo Pérez, J., Thompson, J., Strauss, J., Ortega Granados, A.L., Felip, E., Schmidt, E., Chisamore, M., Madeleine, N., Rayford, A., Lorens, K., Siddiqui, A., Gabra, H., Nautiyal, J., Micklem, D., Lorens, J., Spicer, J.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    58PD NANOSTRING MULTIPLE TARGET PROFILING IDENTIFIES AEG-1 AS AN ESSENTIAL PREDICTOR OF ERLOTINIB OUTCOME IN EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC)

    58PD NANOSTRING MULTIPLE TARGET PROFILING IDENTIFIES AEG-1 AS AN ESSENTIAL PREDICTOR OF ERLOTINIB OUTCOME IN EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC) by Rosell, R, Taron, M, Benlloch, S, Costa, C, Santarpia, M, Moran, T, Carcereny, E, Quiroga, V, Massuti, B, Gimenez-Capitan, A

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: